You are here

Non-invasive assay to discriminate between mild-Traumatic Brain Injury (TBI) and Post traumatic Stress Disorder (PTSD)

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-09-C-0150
Agency Tracking Number: A2-4099
Amount: $748,911.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: A09A-T025
Solicitation Number: 2009.A
Timeline
Solicitation Year: 2009
Award Year: 2011
Award Start Date (Proposal Award Date): 2010-08-05
Award End Date (Contract End Date): N/A
Small Business Information
P.O. Box 8175
Charlottesville, VA -
United States
DUNS: 942413162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Martin Baruch, PhD
 Chief Scientist
 (434) 296-7000
 mcbaruch@comcast.net
Business Contact
 David Gerdt, PhD
Title: President
Phone: (434) 296-7000
Email: davidetc@firstva.com
Research Institution
 University of Virginia
 Sarah White
 
Hospital Drive
Charlottesville, VA 22902-
United States

 (434) 924-8426
 Nonprofit College or University
Abstract

In response to the need, in forward areas, of assessing the likelihood of a mTBI having occurred, the objective of this project is the development of the CBIAS computerized assessment system that will be able to make this determination on the basis of the functioning of the II, III, IV, VI, and VIII cranial nerves. They provide the opportunity to obtain a sensitive and quantitative evaluation of two critical physiological control systems, eye movement and postural balance, that are, because of their high degree of sophistication, very sensitive to cerebral injury. As part of the successful Phase I feasibility study 1. Candidate assessment technologies were down-selected with regard to effectiveness, complexity, and ease of implementation 2. System specifications were developed in consultation with mTBI/PTSD experts and 3. Detailed plans for the clinical studies to be performed under Phase II at several US military sites were developed. The principal aims under Phase II are 1. build of preliminary field prototypes, 2. clinical studies involving 250 mTBI, mTBI/PTSD diagnosed and uninjured military personnel, 3. initiation of FDA approval & design of theatre-deployable systems. Intended for deployment up to and including echelon II, the system will be highly mobile, compact, and rugged.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government